GCG and type 2 diabetes mellitus: Activation of bothpathways ultimately amplifies glucose-stimulated insulin secretionin pancreatic β-cells.6 Additionally,GLP-1 has multiple pharmacological and physiological effects, suchas inhibition of glucagon secretion and pancreatic β-cell apoptosis,which could further benefit patients with T2D,9 while partial agonists such as AMG-837 engage in only the pancreaticβ-cell signaling axis.